Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability.
Although probiotic-containing nutrient formulas for infants and toddlers have become very popular, some adverse effects related to translocation of probiotic strains have been reported. We assessed the safety of probiotic bifidobacteria that have been used in clinical investigations and proven to have beneficial effects, by analyzing mucin degradation activity and translocation ability. Mucin degradation activities of three probiotic bifidobacteria strains; Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63, were evaluated by three in vitro tests comprising growth in liquid medium, SDS-PAGE analysis of degraded mucin residues, and degradation assay in Petri dish. All test strains and control type strains failed to grow in the liquid medium containing mucin as the only carbon source, although good growth was obtained from fecal sample. In the SDS-PAGE analyses of mucin residues and observation of mucinolytic zone in agar plate, the three test strains also showed no mucin degradation activity as the type strains, although fecal sample yielded positive results. In another study, a high dose of B. longum BB536 was administered orally to conventional mice to examine the translocation ability. No translocation into blood, liver, spleen, kidney and mesenteric lymph nodes was observed and no disturbance of epithelial cells and mucosal layer in the ileum, cecum and colon was detected, indicating that the test strain had no translocation ability and induced no damage to intestinal surface. These results resolve the concern about bacterial translocation when using bifidobacteria strains as probiotics, which have been tested in various clinical trials, supporting the continuous use of these probiotic strains without anxiety.
Abe
Fumiaki
F
Food Science & Technology Institute, Morinaga Milk Industry Co., Ltd., 1-83, 5-Chome Higashihara, Zama-City, Kanagawa Prefecture 228-8583, Japan. f_abe@morinagamilk.co.jp
Muto
Masamichi
M
Yaeshima
Tomoko
T
Iwatsuki
Keiji
K
Aihara
Hiroaki
H
Ohashi
Yuji
Y
Fujisawa
Tomohiko
T
D000328:Adult; D000818:Animals; D018988:Bacterial Translocation; D001644:Bifidobacterium / Q000254:growth & development / Q000378:metabolism / Q000472:pathogenicity / Q000502:physiology*; D001769:Blood / Q000382:microbiology; D002244:Carbon / Q000378:metabolism; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000502:physiology; D007668:Kidney / Q000382:microbiology; D008099:Liver / Q000382:microbiology; D008198:Lymph Nodes / Q000382:microbiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009077:Mucins / Q000378:metabolism*; D019936:Probiotics / Q000008:administration & dosage* / Q000009:adverse effects* / Q000378:metabolism; D013154:Spleen / Q000382:microbiology
D009077:Mucins; D002244:Carbon